سعر اتومافوتكس 10مجم 30 كبسولة 2025

Atomafutix 10 mg capsules, pack of 30 (Future Pharmaceutical Industries, Egypt): atomoxetine 10 mg, a non-stimulant selective norepinephrine reuptake inhibitor used for attention-deficit/hyperactivity disorder (ADHD).

• Attention-deficit/hyperactivity disorder (ADHD)Population: Adults and pediatric patients 6 years and olderDailyMed (US National Library of Medicine)
• ADHD as part of a comprehensive treatment programme, initiated by a specialist in ADHDPopulation: Children 6 years and older, adolescents and adultsUK electronic Medicines Compendium (emc)

• Most common (at least 5% and twice placebo) in pediatric studies: nausea, vomiting, fatigue, decreased appetite, abdominal pain and somnolence; in adults: constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction and urinary hesitation.International label, equivalent formulation · DailyMed (US National Library of Medicine)
• Adults: most common adverse events were nausea (26.7%), dry mouth (18.4%), headache (16.3%), decreased appetite (14.9%) and insomnia (11.3%), mostly mild to moderate.International label, equivalent formulation · UK electronic Medicines Compendium (emc)

• Hypersensitivity to atomoxetine or constituents; use with or within 14 days of a monoamine oxidase inhibitor; narrow-angle glaucoma; pheochromocytoma or history of it; severe cardiac or vascular disorders that would deteriorate with clinically important increases in blood pressure or heart rate.International label, equivalent formulation · DailyMed (US National Library of Medicine)
• Hypersensitivity; combination with MAOIs or within 2 weeks of stopping them; narrow-angle glaucoma; severe cardiovascular or cerebrovascular disorders (e.g. severe hypertension, heart failure, cardiomyopathy, life-threatening arrhythmias, cerebral aneurysm, stroke); phaeochromocytoma or history of it.International label, equivalent formulation · UK electronic Medicines Compendium (emc)

• Boxed warning: increased risk of suicidal ideation in pediatric patients 6 years and older in short-term studies (0.4% vs 0% placebo); monitor closely for suicidal thoughts, clinical worsening and unusual behaviour, especially in the first months and after dose changes.International label, equivalent formulation · DailyMed (US National Library of Medicine)
• Severe liver injury (rare, including liver failure): discontinue and do not restart in patients with jaundice or laboratory evidence of liver injury.International label, equivalent formulation · DailyMed (US National Library of Medicine)
• Serious cardiovascular reactions (sudden death, stroke, myocardial infarction) reported; evaluate for cardiac disease before treatment; blood pressure and heart rate may increase and orthostatic hypotension/syncope can occur.International label, equivalent formulation · DailyMed (US National Library of Medicine)

• Monoamine oxidase inhibitors (including linezolid, intravenous methylene blue)Contraindicated together or within 14 days: serious, sometimes fatal reactions (hyperthermia, rigidity, myoclonus, autonomic instability, delirium/coma).DailyMed (US National Library of Medicine)
• Strong CYP2D6 inhibitors (e.g. paroxetine, fluoxetine)Increase atomoxetine exposure; use a longer titration interval (4 weeks) if symptoms fail to improve and the initial dose is tolerated.DailyMed (US National Library of Medicine)
• Antihypertensives and pressor agents (e.g. dopamine, dobutamine)Risk of increased blood pressure: monitor blood pressure more often and adjust dosing as clinically appropriate.DailyMed (US National Library of Medicine)

• Published data are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal/fetal outcomes; some animal studies showed adverse developmental outcomes. A pregnancy exposure registry for ADHD medications exists.International label, equivalent formulation · DailyMed (US National Library of Medicine)
• Clinical data on exposed pregnancies are limited; atomoxetine should not be used during pregnancy unless the potential benefit justifies the potential risk to the foetus.International label, equivalent formulation · UK electronic Medicines Compendium (emc)
• No data on presence in human milk, effects on the breastfed child or milk production; atomoxetine is present in animal milk. Weigh breastfeeding benefits against the mother's need and potential infant effects.International label, equivalent formulation · DailyMed (US National Library of Medicine)

• Atomoxetine: Thought to act through selective inhibition of the presynaptic norepinephrine transporter; the precise mechanism in ADHD is unknown (US label).